SynOx Therapeutics Limited

“Expanded access, sometimes called “Compassionate Use”, “Named Patient Supply”, or “Special Access Schemes/Programs”, refers to the use of an investigational therapy outside a clinical trial when the primary purpose is to diagnose, prevent, or treat a serious condition in a patient. We understand the importance of expanded access programmes, and we recognize the need to have an appropriate policy. Synox Therapeutics will consider the following criteria when considering making emactuzumab available to patients under an expanded access programme: - The patient has a serious or immediately life-threatening disease or condition. - There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition. - Patient enrolment in a clinical trial is not possible. - Potential patient benefit justifies the potential risks of treatment. - Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.”